Literature DB >> 12548609

Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study.

James G Gurney1, Nina S Kadan-Lottick, Roger J Packer, Joseph P Neglia, Charles A Sklar, Judy A Punyko, Marilyn Stovall, Yutaka Yasui, H Stacy Nicholson, Suzanne Wolden, Dawn E McNeil, Ann C Mertens, Leslie L Robison.   

Abstract

BACKGROUND: Survivors of childhood brain tumors (CBTs) are at high risk for a variety of late adverse effects. Most research on long-term effects of CBTs has been comprised of single-institution case series without comparison groups. Research on CBT late effects often is focused on neurologic and sensory outcomes, with less emphasis on other potential targets such as the endocrine and circulatory systems. The current study was conducted to contrast the incidence of endocrine and cardiovascular conditions among CBT survivors as a function of treatment and to determine the risk of occurrence of these conditions relative to a sibling comparison group.
METHODS: As part of the Childhood Cancer Survivor Study (CCSS), treatment data were collected from medical records and self-reported late effects were ascertained from a survey questionnaire of 1,607 CBT patients who survived their disease for 5 or more years. For comparison purposes, questionnaire data were also collected from 3418 randomly selected siblings of participants in CCSS.
RESULTS: One or more endocrine conditions were reported by 43% of CBT survivors. Compared with siblings, CBT survivors had a significantly increased risk of late-onset (>/= 5 years postdiagnosis) hypothyroidism (relative risk [RR] = 14.3; 95% confidence interval [95% CI] 9.7-21.0), growth hormone deficiency (RR = 277.8; 95% CI 111.1-694.9), the need for medications to induce puberty (RR = 86.1; 95% CI 31.1-238.2), and osteoporosis (RR = 24.7; 95% CI 9.9-61.4). One or more cardiovascular conditions were reported by 18% of CBT survivors, with an elevated late-onset risk for stroke (RR = 42.8; 95% CI 16.7-109.8), blood clots (RR = 5.7; 95% CI 3.2-10.0), and angina-like symptoms (RR = 2.0; 95% CI 1.5-2.7). Very few late effects were evident among those treated with surgery only, but risks were consistently elevated for those treated with radiation and surgery, and higher still for those who also received adjuvant chemotherapy.
CONCLUSIONS: Childhood brain tumor survivors are at a significantly increased risk for several adverse endocrine and cardiovascular late effects, particularly if they were treated with radiation and chemotherapy. Lifetime medical surveillance and follow-up for potential toxicities are necessary because treatment-related complications may occur many years after therapy. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11095

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548609     DOI: 10.1002/cncr.11095

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.921


  108 in total

1.  Sleep disturbances in adult survivors of childhood brain tumors.

Authors:  Vikki G Nolan; Roxanna Gapstur; Cynthia R Gross; Lauren A Desain; Joseph P Neglia; Amar Gajjar; James L Klosky; Thomas E Merchant; Marilyn Stovall; Kirsten K Ness
Journal:  Qual Life Res       Date:  2012-06-06       Impact factor: 4.147

2.  Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma.

Authors:  Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Stephen J Russell; Evanthia Galanis; Corey Raffel
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 3.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 4.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

5.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

Review 6.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

Review 7.  Childhood brain tumors: accomplishments and ongoing challenges.

Authors:  Roger J Packer
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.

Authors:  Ki Woong Sung; Do Hoon Lim; Meong Hi Son; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Ji Hye Kim; Yeon-Lim Suh; Yoo Sook Joung; Hyung Jin Shin
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

Review 9.  Growth hormone treatment and risk of recurrence or progression of brain tumors in children: a review.

Authors:  Roberto Bogarin; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2009-01-14       Impact factor: 1.475

Review 10.  Proton therapy for paediatric CNS tumours - improving treatment-related outcomes.

Authors:  Vinai Gondi; Torunn I Yock; Minesh P Mehta
Journal:  Nat Rev Neurol       Date:  2016-05-20       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.